Loading
AURKA (Aurora kinase A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Ovarian cancer and Non-small-cell lung cancer. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for normal spindle positioning during mitosis and for the localisation of NUMA1 and DCTN1 to the cell cortex during metaphase. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Phosphorylates MCRS1 which is required for MCRS1-mediated kinetochore fibre assembly and mitotic progression. Location: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, cytoskeleton, spindle pole; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole; Cell projection, neuron projection (UniProt). Locus 20q13.2 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 0.1-4% | Co-amplification, enriched in neuroendocrine disease | Overexpression and gene amplification of AURKA and MYCN were found in 40% of neuroendocrine prostate cancers and 5% of adenocarcinomas in a profiling series of 7 neuroendocrine, 30 adenocarcinoma and 5 benign tissues validated by immunohistochemistry and fluorescence in situ hybridisation on 37 neuroendocrine, 169 adenocarcinoma and 22 benign samples (Beltran 2011). cBioPortal high-level amplification: AURKA 18 of 444, 4.1%, in prad_su2c_2019 (where 3q and 20q gains inflate the call); 2 of 2,260, 0.1%, in prostate_msk_2024. MYCN amplification 8 of 444, 1.8%, in prad_su2c_2019 and 5 of 2,260, 0.2%, in prostate_msk_2024. | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"AURKA" OR ABSTRACT:"AURKA" OR TITLE:"aurora kinase A" OR ABSTRACT:"aurora kinase A" OR TITLE:"Aurora kinase A" OR ABSTRACT:"Aurora kinase A" OR TITLE:"AurA" OR ABSTRACT:"AurA" OR TITLE:"STK7" OR ABSTRACT:"STK7" OR TITLE:"ARK1" OR ABSTRACT:"ARK1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AURKA, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/aurka.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/aurka.json. Licence CC BY-NC 4.0.